What would it take to prevent Alzheimer’s before it becomes obvious?

In this third and final episode of our series on women’s brain health and Alzheimer’s disease, Noah Volz looks at the system Southern Oregon would need to build if it took prevention seriously.

The numbers are sobering. The lifetime cost of dementia care is estimated at more than $400,000 per person, and much of that burden falls on families through unpaid caregiving and out-of-pocket costs. Oregon already has tens of thousands of people living with Alzheimer’s, and the impact will continue to grow across families, employers, Medicaid, and local healthcare systems.

But this episode is not just about the crisis. It is about what Southern Oregon could build next.

You’ll hear five concrete asks for the region:

• A dedicated Alzheimer’s prevention clinic
• Menopause-literate primary care
• Payment models that reward prevention
• Local readiness for emerging research like the CARE Initiative
• A Southern Oregon Brain Health Coalition

The core question is simple: will Southern Oregon keep waiting until cognitive decline is obvious, or will we build a system that catches risk earlier, supports women in midlife, and makes prevention practical?

This episode is for women in midlife, primary care clinicians, healthcare administrators, payers, policymakers, and anyone who cares about the future of brain health in Southern Oregon.

Subscribe at reimagine-healthcare.org for future reporting, local events, and next steps as this conversation turns into regional action.

This podcast is for educational purposes only and is not medical advice.

Carol is 54, hikes the Siskiyous on weekends, and has been forgetting words mid-sentence for two years. Her doctor ran the standard tests, found nothing, and told her it's just part of getting older.

Her doctor is probably wrong.

This is the first episode in a three-part series on Alzheimer's disease in women — drawing on the research of Dr. Lisa Mosconi, director of the Women's Brain Initiative at Weill Cornell Medicine, and grounded in what Southern Oregon currently has, and critically lacks, for women navigating this risk right now.

In This Episode, You'll Learn:

• Why the standard explanation for women's higher Alzheimer's rate — that women live longer — falls apart the moment you press on it, and what the brain imaging data points to instead
• Why Alzheimer's is a midlife disease that shows up in old age — and why the 20-year preclinical window means Carol's doctor's cognitive test was measuring the wrong moment entirely
• What estrogen is actually doing in the brain, why menopause is fundamentally a brain event before it's anything else, and what Dr. Mosconi's imaging studies found happening to women's brains before their final menstrual period
• The APOE4 number most women with genetic testing have been given — and why that number may be dramatically underestimated because it was calculated on populations that combined men and women
• What Southern Oregon actually has for women like Carol: Asante's neurology department, select gynecology practices willing to discuss hormone therapy, and one nationally recognized integrative practitioner in Ashland — along with an honest account of who can actually access that care
• Why the standard cognitive tests used in most Southern Oregon primary care offices are designed to detect moderate dementia, not prevent it — and what that means for thousands of women currently in the highest-risk window

The uncomfortable truth: Carol's doctor isn't negligent. The system is using the tools it was built with. Those tools weren't designed for what Carol actually needs — and by the time they are, the 20-year window for prevention will have closed.

This episode is for you if:

• You're a woman in your 40s or 50s noticing cognitive changes you can't explain
• You've had APOE4 genetic testing and want to understand what that result actually means for women specifically
• You have a family history of Alzheimer's and want to know what questions to bring to your next appointment
• You believe Southern Oregon can do better for the thousands of women currently in this risk window

Subscribe to the newsletter at reimagine-healthcare.org for episode updates and a list of questions to bring to your next doctor's appointment.

Kathleen's labs had been normal for three years. She was on medication. She was still disappearing.

This final episode of the thyroid series follows Kathleen through the six months after her extended labs changed everything — and makes a direct case for what Southern Oregon's healthcare infrastructure needs to build so that her story becomes the rule, not a lucky accident.

What produced Kathleen's recovery wasn't a system. It was a series of accidents in her favor: the right book, a physician willing to listen, a phone call that took ten minutes and was worth three years. For every patient who gets those accidents, dozens don't.

Here's what the episode covers:

• Why Kathleen was already on combination therapy and still not getting better — and what the pharmacokinetics of oral T3 reveal about how delivery method matters as much as what you're taking
• The honest evidence on levothyroxine monotherapy: why it works for 80 to 85 percent of patients, and what a mortality dataset of over a million people shows about the meaningful minority it doesn't serve
• The 30 percent all-cause mortality reduction seen in patients on combination T4 and T3 therapy — and why that signal hasn't produced the clinical response it would in any other area of medicine
• Why the liver of a patient on levothyroxine with normal TSH may still be relatively hypothyroid — and what that explains about why statins are the most commonly co-prescribed drug alongside thyroid medication
• Desiccated thyroid extract versus synthetic combination therapy: what the blinded crossover trials actually show, what the legitimate concerns are, and where the ideology on both sides parts ways with the evidence
• What compounded controlled-release T3 claims versus what the only published pharmacokinetic study of those products actually found
• The functional medicine interventions with genuine evidence behind them — and the ones that go well beyond it
• What Kathleen's six-month lab results looked like: free T3, reverse T3 ratio, LDL cholesterol, anti-TPO antibodies — and what changed in her life when the numbers finally moved
• Five specific infrastructure changes Southern Oregon could build now: a shared diagnostic protocol, care coordination pathways between conventional and functional providers, insurance advocacy for comprehensive testing, regional CME, and a prospective outcomes registry

The uncomfortable truth: Good medicine happens when the patient's lived experience is treated as data and the physician's training is a starting point for inquiry, not a closed file. For Kathleen, that combination arrived three years late. The science, the practitioners, and the patients are already here. What's missing is the connective tissue that turns motivated individuals into a system that reliably serves everyone who needs it.

This episode is for you if:

• You've completed the series and want to understand what treatment options the evidence actually supports
• You're a Southern Oregon provider looking for a roadmap grounded in peer-reviewed research
• You believe the parallel silo between conventional and functional medicine is costing patients — and you want to see what closing it looks like in practice

Subscribe to the newsletter at reimagine-healthcare.org for updates on thyroid care in Southern Oregon and new episodes.